NV-BITSENSING
bitsensing , a South Korean radar technology startup, introduces the new mini Healthcare Radar, mini-H , the smallest high-resolution 60GHz IoT Radar sensor in the lineup. The innovation behind the mini-H demonstrates the company’s industry leading expertise in designing and building cutting edge radar technology that can transform healthcare, automotive, mobility, smart home, security, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005325/en/
Dr. Jae-Eun Lee, CEO of bitsensing, a seasoned engineer in radar technology and formerly a part of the automotive world at Mando Corp., knows what it takes to create a safe and conveniently connected world. “Revolutionary technologies such as mini-H are propelling what is possible in all facets of our daily lives,” says Lee. “We at bitsensing are committed to integrating these groundbreaking radar technologies to help build smart lives and smart cities which ultimately elevates the quality of life for all.”
The advanced mini-H sensor attaches to the wall and can detect, in real-time, presence, movement, breathing or lack thereof, and falls by measuring breathing patterns and pulsating vessels without the use of intrusive cameras or wearables.
Specifically designed for a more intelligent and safer monitoring system for telehealth, mini-H can be used in dark or wet places and works regardless of clothes or blankets. The Bluetooth and WiFi communication module allows for a seamless transfer of data from the radar to dashboards or the app for easy tracking. This fully wireless product makes it quick and easy to implement software advancements, ensuring the product is always up to date. The sleek, compact aesthetic of the product also allows for an easy integration while the plug and play style provides instant monitoring of activities with the option to adjust settings for optimal personalization.
As a leading radar solution company, bitsensing offers complete end to end services, creating customizable radars like the mini-H that exceed industry standards in convenience and security. The nimble structure of bitsensing allows the team to deliver powerful products quickly while working directly with end customers across a large range of industries to ensure satisfaction and broaden their horizons of what is possible in a smart life.
CES attendees can visit bitsensing’s virtual booth to learn more about the mini-H from January 11-14, 2021. To view the mini-H informational product video, please visit here . If you are interested in learning more about our radar solution offerings, please visit www.bitsensing.com .
mini-H Product Specifications
Specs subject to change without notice. All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
General Spec |
|
Centered Frequency |
61 GHz |
Bandwidth |
3.75 GHz |
Communication Interface |
WiFi or Bluetooth, RS485 |
Coverage Spec |
|
Detection Range |
0.2m ~ 2.5m |
Field of View |
±60° (Azimuth), ±60° (Elevation) |
Feature |
Moving, Falling, Presence, Apnea |
Vital Sign |
Respiration* |
Resolution |
0.04m |
Electrical Spec |
|
Operating Voltage |
7V ~ 14V |
Current Consumption |
Max 3W |
Mechanical Spec |
|
Dimensions |
50 x 50 x 15 mm |
Weight |
100g** |
Connector |
Open terminal Cable |
Environment Spec |
|
Operating Temperature |
-20 ~ +85 °C |
* The data driven by respiration detection may be limited and is designed to be used for apnea detection |
** The weight is without cable |
About bitsensing
bitsensing is an imaging radar technology company committed to building safer smart cities and elevating connected living by designing cutting-edge sensor fusions and AI solutions bringing an unprecedented level of intelligence to smart living. Founded in 2018 by seasoned automotive experts, bitsensing is one of the only startups delivering optimal technologies that meet and exceed the high level of safety and convenience that the industry demands. bitsensing is transforming possibilities to bring democratization of smart life in healthcare, automotive, mobility, smart home, security, and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom